Redhill Biopharma Ltd. (NASDAQ:RDHL)’s share price traded down 2% on Thursday . The stock traded as low as $5.17 and last traded at $5.38. 315,610 shares changed hands during trading, an increase of 254% from the average session volume of 89,169 shares. The stock had previously closed at $5.28.

Several equities analysts have recently weighed in on the company. HC Wainwright set a $33.00 price target on Redhill Biopharma and gave the company a “buy” rating in a report on Wednesday, July 26th. Roth Capital set a $27.00 price target on Redhill Biopharma and gave the company a “buy” rating in a report on Monday, July 31st. Zacks Investment Research cut Redhill Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, July 29th. Seaport Global Securities assumed coverage on Redhill Biopharma in a report on Friday, October 6th. They set a “buy” rating and a $19.00 price target on the stock. Finally, UBS AG assumed coverage on Redhill Biopharma in a report on Wednesday, September 13th. They set a “reduce” rating on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. Redhill Biopharma currently has an average rating of “Buy” and a consensus price target of $23.35.

A number of institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC raised its holdings in Redhill Biopharma by 144.1% in the 1st quarter. Renaissance Technologies LLC now owns 62,000 shares of the biotechnology company’s stock worth $595,000 after purchasing an additional 36,600 shares during the period. D.A. Davidson & CO. raised its holdings in Redhill Biopharma by 10.0% in the 2nd quarter. D.A. Davidson & CO. now owns 44,000 shares of the biotechnology company’s stock worth $379,000 after purchasing an additional 4,000 shares during the period. Family Management Corp raised its holdings in Redhill Biopharma by 51.5% in the 2nd quarter. Family Management Corp now owns 25,750 shares of the biotechnology company’s stock worth $222,000 after purchasing an additional 8,750 shares during the period. Oppenheimer & Co. Inc. raised its holdings in Redhill Biopharma by 10.8% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 25,569 shares of the biotechnology company’s stock worth $220,000 after purchasing an additional 2,500 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in Redhill Biopharma by 13.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 12,005 shares of the biotechnology company’s stock worth $103,000 after purchasing an additional 1,440 shares during the period. 10.97% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This piece was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/11/redhill-biopharma-ltd-rdhl-stock-price-down-2.html.

Redhill Biopharma Company Profile

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Receive News & Stock Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related stocks with our FREE daily email newsletter.